Health TrialsbyHealthPanel

An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

ConditionsPulmonary Arterial HypertensionPulmonary Hypertension, Interstitial Lung Disease
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
Age18+
SponsorInsmed Incorporated

About this trial

The purpose of this study is to provide continued access to TPIP for participants who have successfully completed the open-label extension (OLE) studies of INS1009-203 for PAH or INS1009-212 for PH-ILD.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

The participant is ineligible for or cannot be treated satisfactorily with alternative commercially available therapy for PAH or PH-ILD.

Participant provides their informed consent to participate as per local requirements.

Participant must have successfully completed the OLE INS1009-203 or INS1009-212 studies.

Based on the treating physician's judgement on participant's medical history and an evaluation of the overall risk-benefit profile, the participant will be determined to be suitable for continued TPIP treatment within this program.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Treprostinil Palmitil

    Drug

    Treprostinil Palmitil Inhalation Powder

Treatment groups

No treatment groups listed

Trial outcomes

This trial has no outcomes listed.

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Insmed Incorporated

Lead sponsor

Source ClinicalTrials.gov
Apply now